Alkermes (NASDAQ:ALKS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives ...

Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th ...

Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - - ...

Alkermes is positioned for outperformance due to its conservative cash-heavy balance sheet and high-margin business model.

The singer-songwriter talks about the importance of having the language to express one's experiences to others. Marcus King on Battling Feelings of “Terrible Hopelessness” with Meaningful Communicatio ...

Alkermes ALKS has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ratings ...

Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise ...

Baird raised the price target for the Alkermes plc (NASDAQ:ALKS) stock to “an Outperform”. The rating was released on March 19, 2024, according to finviz. The research report from JP Morgan has ...

Investors need to pay close attention to About Alkermes (ALKS) stock based on the movements in the options market lately.

DUBLIN, May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk.